ArticleBritish journal of cancer2001
A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.International journal of clinical oncology · 2020Guideline
- Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America.International journal of cancer · 2011Pooled it
- Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer.International journal of clinical oncology · 2008Trial
- A potential mutation-defined POLE/MMR/TP53 group classifications to stratify BRCA wild type epithelial ovarian cancer.Journal of ovarian research · 2026Article
- Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted.International journal of molecular sciences · 2022Review
- DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?Biomedicines · 2021Review
- Inflammation-associated microsatellite alterations: Mechanisms and significance in the prognosis of patients with colorectal cancer.World journal of gastrointestinal oncology · 2018Review
- Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer.DNA repair · 2016Review
- Apoptosis and molecular targeting therapy in cancer.BioMed research international · 2014Review
- Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.Frontiers in oncology · 2014Review
- ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.British journal of cancer · 2013Article
- DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.Gynecologic oncology · 2012Article
- MutS homologue hMSH5: role in cisplatin-induced DNA damage response.Molecular cancer · 2012Article
- Genotype to phenotype: analyzing the effects of inherited mutations in colorectal cancer families.Mutation research · 2010Review
- Targeted therapies: tailored treatment for ovarian cancer: are we there yet?Nature reviews. Clinical oncology · 2010Article
- MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.British journal of cancer · 2009Article
- Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs.Journal of experimental & clinical cancer research : CR · 2009Article
- Mismatch repair and treatment resistance in ovarian cancer.BMC cancer · 2006Article
- Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients.Breast cancer research : BCR · 2005Article
- Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells.Oncogene · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To clarify the mechanism of acquired CDDP resistance in ovarian cancer, we compared the microsatellite instability (MSI) by the amplification of 10 microsatellite loci and immunohistochemical detection of hMSH2 and hMLH1 expression between the primary resected tumours and the secondary resected residual tumours after 5 or 6 courses of CDDP-based chemotherapy in the 24 cases of ovarian cancer. Of the 24 primary resected tumours, 9 (37.5%) showed MSI (7 cases of MSI-L, 2 cases of MSI-H), while 15 (72.5%) were microsatellite stable tumours (MSS). The primary tumours also had MSI in the residual tumours after CDDP-based chemotherapy. However, all of the cases with MSS in the primary resected tumours exhibited MSI (2 cases were MSI-L, and 13 cases were MSI-H) in the residual tumours after CDDP-based chemotherapy (P< 0.001). Furthermore, 11 (73.3%) of these cases which changed from MSS to MSI also had a change in the expression of hMLH1 from positive to undetectable (P< 0.001). Our data suggest that tumour MSI changes during CDDP-based chemotherapy, and that the loss of hMLH1 expression is one of the factors that has the greatest effect on this transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.